Finance entity
markets is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention AbbVie, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 125-day span. At 5, the average consequence score sits below the same-window beat average of 6.4.
Last mentioned: Jul 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention AbbVie, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 125-day span. At 5, the average consequence score sits below the same-window beat average of 6.4. They are less corroborated than the beat average, carrying 2.5 original sources each against 3 for the same window. iShares U.S. Pharmaceuticals ETF appears in 2 tracked Finance stories published from March 17, 2026 through July 19, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1554 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering iShares U.S. Pharmaceuticals ETF. Shared-story counts are live from our verified record — not editorial picks.
The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Source: Cory Renauer (us) · fool.com
BlackRock has announced quarterly distributions for three major healthcare-focused iShares ETFs, reflecting the varied cash flow profiles across the pharmaceutical, medical device, and healthcare provider sub-sectors. The distributions, led by the $0.2845 per share payout for the U.S. Pharmaceuticals ETF (IHE), come as investors weigh sector-specific regulatory pressures against robust balance sheets.
Source: Seeking Alpha · Seeking Alpha
iShares U.S. Pharmaceuticals ETF is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
